Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Michele Hu speaks at the Annual Parkinson's UK Flagship Lecture at the Royal Institution.

On 6 November 2014 Dr Michele Hu from the Nuffield Department of Clinical Neurosciences and Dr Alistair Noyce from UCL gave presentations about the search for biomarkers, stratification and how this could lead to more bespoke treatments for Parkinson’s.

The speakers were joined by the newly appointed Parkinson's UK Director of Research and Innovation, Dr Arthur Roach, for a Q&A session after the talks. Colin Cheesman, a Parkinson's UK trustee, gave closing remarks.

The lecture was attended by around 300 people, largely those affected by Parkinson's but also students and other supporters of the charity. 

Read more about our work on Parkinson's and other movement disorders.

 

“Thank you so much for a fascinating evening yesterday. It was really exciting to hear what kind of projects our fund raising is supporting. All the speakers were excellent and took great trouble to make the talks clear and informative and the final speaker giving a patient's view was very moving.”
- Event attendee

 

 

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.